Keros Therapeutics, Inc. (KROS) Misses Q1 EPS by 14c

Keros Therapeutics, Inc. (NASDAQ: KROS) reported Q1 EPS of ($1.26), $0.14 worse than the analyst estimate of ($1.12).

For earnings history and earnings-related data on Keros Therapeutics, Inc. (KROS) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• HP shares slide as tech giant forecasts 2027 PC market slump
• BMO Capital Reiterates Market Perform Rating on Axalta Coating Systems (AXTA)